Search Results

FDA Approves Immune Checkpoint Inhibitor Drug for Patients with Resectable Locally Advanced Head and Neck Cancer, Backed by Dana-Farber Research

Our findings have great promise in being able to establish personalized cancer medicine specialized for tumor recurrence and create novel inhibitors that restore tumor response to immunotherapy.

80 percent of patients with locally advanced mismatch repair-deficient (MMRd) solid tumors who were treated with immunotherapy avoided surgery.

A Dana-Farber-led trial shows pembrolizumab before and after surgery significantly boosts event-free survival in early-stage TNBC—marking the first major progress in over 20 years.

Research Lays the Foundation for Devising Immunotherapeutic Strategies Specifically Designed to Target Brain Metastases in Breast Cancer Patients

Recent clinical trials investigating dendritic cell vaccines for mesothelioma have shown encouraging results